Placing a Single-Use Medical Device in Brazil: The 2026 ANVISA Route

Which Brazilian instruments govern a foreign single-use device in 2026?

Entering the Brazilian healthcare market with sterile single-use devices—whether urological consumables, endovenous laser fibers, negative pressure wound therapy (NPWT) dressing kits, or catheter securement devices—requires navigating an integrated statutory matrix administered by the National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária — ANVISA)¹. For international manufacturers and Brazilian medical distributors, evaluating regulatory feasibility begins by isolating the binding administrative resolutions (Resoluções da Diretoria Colegiada — RDC) and normative instructions (Instruções Normativas — IN) that dictate product classification, dossier architecture, quality system compliance, and post-market tracking.

The cornerstone of Brazilian medical device regulation is RDC nº 751/2022, which entered into force on 1 March 2023, repealing the legacy framework of RDC 185/2001 and internalizing Mercosur GMC Resolution 25/2021⁵, ⁶, ²¹. RDC 751/2022 governs the classification, petitioning, and post-authorization lifecycle of all medical devices (dispositivos médicos), while in vitro diagnostic (IVD) products are segregated under RDC 830/2023. Compliance with essential clinical, electrical, and mechanical benchmarks is governed by RDC nº 848/2024, which harmonized Brazil's essential safety and performance requirements with IMDRF standards⁷. Understanding how these baseline norms interact with manufacturing quality mandates, reliance mechanisms, and electronic registry systems is vital before drafting commercial distribution contracts.

Notification or registro: which regime does the device fall under?

Article 5 of RDC 751/2022 places medical devices in four risk classes: Class I (low risk), Class II (medium risk), Class III (high risk), and Class IV (maximum risk)⁶. Article 6 subjects Classes I and II to notificação. Article 7 subjects Classes III and IV to marketing authorization (registro)⁶. That class, not a European or Chinese class, selects the gateway the Brazilian holder must use:

• Notificação (Notification): Mandatory pathway for Risk Class I and Class II devices. Characterized by an administrative declaration without pre-market technical dossier review, permanent non-expiring legal status, and a statutory turnaround ceiling.
• Registro (Marketing Authorization): Mandatory pathway for Risk Class III and Class IV devices. Requires exhaustive technical review of clinical, mechanical, and sterilization dossiers, prior validation of manufacturing Good Practices, ten-year legal validity, and formal revalidation proceedings.

Risk classification rules and the non-technical analysis ceiling

Annex I of RDC 751/2022 sets out 22 classification rules⁶. Article 4 defines duration of use as transitional (continuously less than 60 minutes), short-term (continuously from 60 minutes up to 30 days), and long-term (continuously more than 30 days)⁶. Article 8 applies the rules according to intended purpose, classifies an accessory separately from the device it accompanies, and requires the strictest applicable rule where more than one rule fits⁶. For a sterile consumable, the buyer has to answer those questions — duration, whether the device is surgically invasive, and whether it only transmits energy from another device — before anyone can name a Brazilian class.

For Class I and II notifications, Article 10 paragraph 6 of RDC 751/2022 says processing occurs routinely within 30 days after the applicant submits the petition⁶. The notification guidance page states a maximum of 30 calendar days to issue the notification number, and that the period may be well below that ceiling⁴. Article 10 paragraph 5, quoted in Voto nº 65/2026, states that notification petitions are regularized without prior technical analysis of the technical file, without prejudice to later documentary or inspection review¹⁷. Publication in the Diário Oficial da União (DOU) is sufficient proof of the grant⁴. Article 28 exempts notified products from revalidation⁶. The English regulation page states that a notification does not expire, and that it may be cancelled on request, on reassessment, where irregularities cannot be resolved, or where fraud is found¹. Fees are charged per petition. One Class II notification file, Voto nº 441/2024, records a payment of R$ 2,987.17 on 25 November 2022 and states that the product in that file undergoes compulsory INMETRO certification¹⁸. That payment is a 2022 case record, not a current fee schedule. Compulsory INMETRO certification applies to the devices ANVISA lists for it, under Article 13, item III, and Article 14, item VI, of RDC 751/2022⁶, not to every consumable.

Later review is real. Voto nº 65/2026 concerns a polypectomy snare notified as Class II in 2019. After review, the technical area treated it as Class III under RDC 751/2022 and asked for the Class III documentation. The holder requested cancellation, published on 26 May 2025, because it no longer wanted to commercialize the product. The board refused an exceptional request to sell the remaining stock: the units had been notified as Class II and did not meet the Class III requirements, including a CBPF¹⁷. Readers comparing Latin American gates can use the Mexico market-placement guide for the COFEPRIS route. It does not decide an ANVISA class.

Why the EU-to-Brazil class mapping is an approximation, not law

A European class is not a Brazilian class. Consultants often print a one-step map — EU Class I to Brazil Class I, Class IIa to Class II, Class IIb to Class III, Class III to Class IV — as if RDC 751/2022 enacted that table. It did not. Article 5 paragraph 2 assigns the classification to ANVISA when application of the rules leaves a doubt⁶.

The rules themselves have to be read. Rule 6, for example, places surgically invasive devices for transitional use in Class II unless a listed exception applies, and the energy exception in that rule is ionizing radiation, which is Class III⁶. A device that supplies non-ionizing energy is not moved by that clause. Article 8 paragraph 6 still requires the strictest rule that fits the intended purpose. A distributor classifies the device against Annex I. A CE certificate does not do that work.

Who holds the authorization when the manufacturer is abroad?

The English regulation page states that foreign companies cannot make the administrative arrangements to be granted marketing authorizations directly by ANVISA. They must have partner companies legally constituted in Brazil that are legally responsible for the products imported and distributed in Brazilian territory¹. RDC 751/2022 Article 4, item VIII, defines the holder as the public or private legal entity, manufacturer or importer, responsible for the device in Brazilian territory and holding the grant of commercialization⁶.

The Brazilian registration holder (detentor) and importer AFE stack

That Brazilian holder is legally responsible for the device in Brazil, including post-market vigilance (tecnovigilância), adverse-event reporting, field actions, and liaison with ANVISA¹. The commercial choice is who that holder is:

• Commercial distributor as holder: the distributor files and owns the authorization. A later change of holder is a transfer of ownership. IN 426/2026 Article 8 cites RDC 903/2024 for that transfer, and Voto nº 21/2026 describes RDC 903/2024 as the successor to RDC 102/2016. The foreign factory does not move the number by ending the distribution contract.
• Independent Brazilian holder: a company constituted in Brazil holds the authorization and can authorize one or more distributors to import. Changing distributors then does not require a new product regularization, provided the holder remains the company named on the ANVISA record.

In addition to corporate constitution, any Brazilian entity importing, storing, or distributing medical devices must possess an active Company Operating Authorization (Autorização de Funcionamento de Empresa — AFE) issued by ANVISA covering the specific activity class (armazenar, distribuir, expedir, importar). Furthermore, the importer's physical facility must hold a valid Local Sanitary Operating License (Licença Sanitária or Alvará Sanitário) issued by the municipal or state health surveillance department (VISA), backed by a qualified Technical Manager (Responsável Técnico — RT) registered with their respective professional council (such as CRF for pharmacists or CREA for biomedical engineers).

The 14 August 2026 milestone: Solicita subject code 80326 and the Código Único

On 14 August 2026, ANVISA implemented a major administrative digitalization measure governing foreign manufacturing plants: Cadastro de fabricantes internacionais de dispositivos médicos (Risco I e II) agora é eletrônico². Under this reform, all petitions to create, modify, or inactivate international manufacturing sites producing Class I and II medical devices (including IVDs) must now be submitted exclusively via ANVISA's electronic Solicita system using Subject Code 80326 (Código de Assunto 80326)².

When the petition is granted, the cadastro produces the Código Único de Fabricante Internacional². The 14 August 2026 notice says this code is consulted in the Portal de Consultas, or on the product-petition screen, and that imported-product regularization must use it. Incomplete documentation or an unsigned form will not be granted². If 10 business days pass after protocol and the code is still unavailable, and the company has not received a letter stating the reasons for rejection, the notice tells the user to request support through ANVISA's official service channels². Petition status is followed in Situação de Documentos Técnicos², ¹⁹. For Class III and IV plants the notice leaves the procedure unchanged: manufacturer identification continues together with the CBPF petition².

In August 2026 ANVISA also published two orientation manuals, one for IVD regularization and one for Class I and II health-material notifications³. The notice describes them as orientative material for manufacturers, importers, and legal representatives, intended to standardize dossier instruction and reduce the inconsistencies that generate technical-deficiency letters and rejections, as part of the queue-reduction project³.

When does the B-GMP certificate block the petition?

Quality management verification in Brazil is governed by Brazilian Good Manufacturing Practices (Boas Práticas de Fabricação — B-GMP), consolidated under RDC nº 665/2022¹³. Unlike jurisdictions that accept a generic ISO 13485 certificate, ANVISA operates its own formal statutory inspection and certification mechanism: the Certificado de Boas Práticas de Fabricação (CBPF)¹². Understanding when the CBPF represents an immovable gate is the single most critical timeline planning factor for an overseas manufacturer.

RDC 687/2022 manufacturing unit scope and sterile packaging

RDC 751/2022 Article 14, item V, tells the applicant for a marketing authorization to submit a CBPF issued by ANVISA or proof that the CBPF application has been filed⁶. Paragraph 2 of that article accepts the protocol of the CBPF application so that analysis of the marketing-authorization petition can start. Paragraph 3, and Article 10 paragraph 8, make the grant conditional on publication of a valid CBPF⁶. Voto nº 41/2026 states the same class split in operational language: Class III and IV products require the CBPF in the registration instruction, and Class I and II notifications do not include the certificate as a mandatory document, while Good Practice obligations remain¹⁵. A Class III file can therefore be opened with proof that the CBPF petition is in process. It cannot be granted until the certificate is published.

Voto nº 41/2026 quotes Article 3 of RDC 687/2022. Certification covers a Class III or IV manufacturing unit that produces a finished device in its own name or for another company, or that performs final release of the finished device together with at least one production step. The quoted text excludes design, distribution, sterilization, packaging, and labeling from the production step that satisfies that second limb¹⁵. The same vote notes that the resolution's commented text gives sterile-barrier conditioning of sterile devices as an example of production, and it records a 2026 technical note that listed primary packaging among production operations while treating quality control of semi-finished goods, grouping, final labeling, release, storage, and distribution as not production¹⁵. In the case, the legal manufacturer that received product, controlled quality, labeled, released, and warehoused was held not to be the certifiable unit. The certificates accepted on the registration were those of the plants that manufactured¹⁵. The buyer question is which site performs the production step ANVISA will certify. The legal manufacturer's letterhead is not that answer by itself.

RDC 850/2024 and the 4-year MDSAP validity rule

Historically, obtaining a CBPF required either an on-site physical inspection by ANVISA inspectors abroad—incurring significant delays—or reliance on the Medical Device Single Audit Program (MDSAP). Previously, CBPFs granted under MDSAP were valid for only two years, creating continuous renewal friction. This operational bottleneck was decisively eliminated with the promulgation of RDC nº 850/2024, enacted in April 2024, which amended RDC 497/2021¹², ¹⁴.

RDC 850/2024 extends the validity of CBPF certificates granted through MDSAP from two years to four years¹², ¹⁴. A two-year renewal statement for the MDSAP route describes the period before that resolution. Factories preparing an audit package can use the guide on verifying an ISO 13485 or MDSAP audit certificate to read the scope statement against the manufacturing site that will be named in the Brazilian file.

Can a CE mark, 510(k), or NMPA registration speed up ANVISA?

A frequent commercial misconception is that holding a European CE mark under the MDR or a National Medical Products Administration (NMPA) Class II or III registration in China automatically provides an accelerated pathway or waiver in Brazil. Under Brazilian administrative law, this assumption is false.

IN 290/2024 AREE criteria and the four recognized authorities

Regulatory reliance in Brazil is codified under Instrução Normativa IN nº 290/2024, which took effect on 3 June 2024 pursuant to the broader reliance framework of RDC nº 741/2022⁸. IN 290/2024 establishes an optimized technical review procedure (procedimento otimizado de análise) for medical devices and IVDs based on evaluation reports issued by Equivalent Foreign Regulatory Authorities (Autoridades Reguladoras Estrangeiras Equivalentes — AREE)⁸.

Under Article 6 of IN 290/2024, ANVISA explicitly limits the recognized AREE roster to exactly four national regulatory agencies⁸, ⁹:

• Australia: Therapeutic Goods Administration (TGA) — verified by an active Australian Register of Therapeutic Goods (ARTG) inclusion.
• Canada: Health Canada (HC) — verified by an active Medical Device Licence (MDL).
• United States: Food and Drug Administration (FDA) — verified by a 510(k) Premarket Notification clearance letter, Premarket Approval (PMA) order, or De Novo classification order under Section 513(f)(2).
• Japan: Ministry of Health, Labour and Welfare (MHLW) / Pharmaceuticals and Medical Devices Agency (PMDA) — verified by a formal Pre-Market Approval (Shonin).

Why CE marks and NMPA registrations buy no procedural shortcut

Article 6 of IN 290/2024 names four authorities. It does not name a European notified body or China's NMPA⁸. A CE mark or an NMPA registration can sit in the technical dossier as clinical, biocompatibility, or bench evidence. It does not open the optimized procedure. The petition follows the ordinary route in RDC 751/2022 or, for an IVD, RDC 830/2023⁸.

IN 290/2024 Article 7 adds two conditions: the device is authorized by at least one authority listed in Article 6, and the proof of that authorization refers to a device essentially identical to the one submitted in Brazil, including the indications and the manufacturer⁸. Article 4 excludes devices the AREE itself authorized through an abbreviated route similar to ANVISA's optimized procedure; those petitions follow the ordinary route⁸. Article 9 allows ANVISA, after reading the AREE file, to choose the ordinary route and to tell the company why. Article 13 keeps the decision with ANVISA, independent of the AREE's conditions⁸.

How long does each route take, and how long does the authorization last?

When calculating time-to-market and contract timelines, distributors and manufacturers must differentiate between statutory regulatory review ceilings and real-world operational processing times published in ANVISA's petition lifecycle dashboards.

Statutory review windows

For Class I and II notification, the ceiling is the one already stated: routinely within 30 days after submission under Article 10 paragraph 6, and a maximum of 30 calendar days on the notification page, which also says the period may be well shorter⁴, ⁶. For an imported Class III or IV device, Article 14 item IV requires proof of marketing authorization, a certificate of free sale, or an equivalent document from the country of manufacture or commercialization⁶. Teams preparing that document can use the guide on checking a certificate of free sale before it goes into a petition. Article 13's notification list asks for the legal manufacturer's authorization statement. It does not repeat that free-sale item.

Law nº 6.360/1976, Article 12 paragraph 3, as amended by Law nº 13.411/2016, says the registration shall be granted within a maximum of 90 days from the filing date, except where the applicant fails to observe the law or its regulations²⁴. RDC 751/2022 Article 10 paragraph 2 points assessment of marketing-authorization documents to the deadlines in Brazilian health legislation⁶. IN 290/2024 Article 10 states that the optimized procedure does not change the chronological order of petitions⁸. The instruments read for this guide state those two rules. They do not publish a separate month-count for an ordinary registro or for a reliance petition.

The 10-year registro clock, revalidation window, and caducidade

Under Article 11 of RDC 751/2022, an approved Class III or IV registro is legally valid for ten years, counted strictly from the date of its publication in the Diário Oficial da União (DOU)⁵, ¹⁶. Commercial teams must discard outdated advice derived from RDC 185/2001 asserting a five-year validity term; ten years has been the binding statutory baseline since RDC 751/2022 took effect¹⁶.

Article 27 paragraph 2 of RDC 751/2022 requires the revalidation petition to be filed within the period in RDC nº 250/2004⁶. In Voto nº 21/2026, GGTPS restated Article 1 of that resolution as a filing window with a maximum antecedence of 12 months and a minimum antecedence of 6 months before the expiration day¹⁶. In that file the holder had not requested revalidation in the window. GGTPS stated that the registration should be published as caducidade, and that no current rule authorizes manufacture, import, commercialization, or display for consumption of a device whose registration was not revalidated¹⁶. The board still granted a separate, exceptional 12-month exhaustion of stock already manufactured during the registration's validity. That exception was for named lots. It did not restore the registration.

What does the 2026 UDI system add to a Brazil file?

Unique Device Identification in Brazil is established by RDC nº 591/2021, which mandated the progressive assignment, carrier marking, and database uploading of UDI identifiers (UDI-DI and UDI-PI) based on international GS1 or HIBCC standards¹⁰.

IN 426/2026 and the SIUD database operational since 1 March 2026

The operational cornerstone of the Brazilian UDI architecture is Instrução Normativa IN nº 426/2026, enacted on 13 February 2026 and published in the DOU on 18 February 2026, with an effective implementation date of 1 March 2026¹¹. IN 426/2026 officially activated ANVISA's digital national database: the Sistema de Identificação Única de Dispositivos Médicos (SIUD)¹⁰.

IN 426/2026 requires the UDI data transmitted to SIUD to match the device ANVISA authorized, and it places that equivalence on the Brazilian holder¹¹. Only the UDI-DI is transmitted in the data set. The holder keeps the UDI-PI in its quality system under RDC 665/2022¹¹. The holder may authorize a third-party user in SIUD to transmit on its behalf. Article 10 leaves transmission legally with the holder, and Article 15 makes breach of the instruction a sanitary infraction under Law nº 6.437/1977¹¹. Article 7 allows corrections of published UDI data for 60 calendar days from the publication date of those data. After that period, only data that do not require a new UDI-DI may be changed as Annex II of RDC 591/2021 provides. Where a change does require a new UDI-DI, Article 7 paragraph 3 requires the substitution in SIUD within 30 calendar days from DOU publication of the alteration¹¹. Article 8 is the transfer rule: the RDC 903/2024 transfer of ownership is finished first, and the successor then transmits UDI-DI for the new regularization numbers within 30 days after the cancellation and transfer resolutions take effect¹¹. Article 9 is the inactivation rule: within 30 days the holder records the discontinuation date when it ends supply in Brazil, when the authorization expires, or when the regularization is cancelled. For cancellation, that 30-day count starts on the first business day after the DOU publication¹¹.

Phased transmission deadlines and 60-day correction duties

Compulsory SIUD transmission uses the year counts in Article 15 of RDC 591/2021, as amended by RDC nº 884/2024: 3.5 years for Class IV, 4 years for Class III, 5 years for Class II, and 6 years for Class I²². Paragraph 3 of that article starts the database-transmission count when ANVISA publishes the instruction stating that the database can receive the data. IN 426/2026 Article 11 applies those periods from this instruction's effective date, 1 March 2026¹¹, ²². Until the class date, transmission is voluntary. Devices already on the market when the instruction took effect may also be transmitted voluntarily¹¹. Label marking is a different clock, counted from RDC 591's entry into force on 10 January 2022. GGTPS Ofício Circular nº 2/2025 states that devices manufactured from 10 July 2025 (Class IV), 10 January 2026 (Class III), 10 January 2027 (Class II), and 10 January 2028 (Class I) must carry the UDI on the label and packaging, with two further years where the carrier is placed on a reusable device itself²³. The 2029–2032 dates below are the SIUD transmission dates, not the first dates a label can need a code.

• Risk Class IV: compulsory SIUD transmission on 1 September 2029 (3.5 years from 1 March 2026).
• Risk Class III: compulsory SIUD transmission on 1 March 2030 (4 years from 1 March 2026).
• Risk Class II: compulsory SIUD transmission on 1 March 2031 (5 years from 1 March 2026).
• Risk Class I: compulsory SIUD transmission on 1 March 2032 (6 years from 1 March 2026).

How do you verify a Brazilian authorization before signing a distribution deal?

Before executing a distribution agreement, commercial representation contract, or tender supply commitment in Brazil, distributor executives and procurement teams must conduct an unassailable four-step due diligence verification across ANVISA's official public registry platforms.

The four official lookups: Consultas, Código Único, DOU, and regularized list

Do not rely on a distributor's PDF certificate, marketing brochure, or supplier letter. Execute these four statutory lookups directly:

1. Lookup 1: ANVISA Portal de Consultas. Access consultas.anvisa.gov.br under 'Dispositivos Médicos'. Input the claimed 11-digit Brazilian registration/notification number (starting with 8, e.g., 8XXXXXXYYYY). Confirm: (a) registration status is 'Ativo / Válido'; (b) corporate name and CNPJ of the Brazilian Detentor match your contractual partner; and (c) exact trade name, models, and specifications correspond to the products being procured.
2. Lookup 2: International Manufacturer Screen & Código Único. For Class I/II devices regularized post-August 2026, navigate to the international companies consultation screen. Verify that the foreign factory name and site address possess an active Código Único de Fabricante Internacional assigned via Solicita Subject Code 80326. For Class III/IV devices, verify that the manufacturing site possesses an active, published CBPF under RDC 665/2022.
3. Lookup 3: Diário Oficial da União (DOU) Publication. Search the official federal gazette (in.gov.br) for the publication extract corresponding to the original grant or most recent revalidation. Under Brazilian administrative law, DOU publication is the legally sufficient proof of market access. Confirm the date of publication to verify the ten-year validity clock.
4. Lookup 4: Lista de Dispositivos Médicos Regularizados. Download ANVISA's open-data master dataset of regularized devices²⁰. Confirm that the product appears in the active registry and cross-check its technical manager (RT) and authorized commercial packaging formats.

Worked portfolio examples: circumcision device, laser fiber, and protective pants

To demonstrate how the regulatory decision tree functions across diverse single-use categories, we examine three sterile product archetypes passing through ANVISA's classification gates:

Example A: Disposable circumcision device. The product page for the self-detaching circumcision ring describes a single-use ring supplied sterile. A ring that remains in place for days is short-term use under Article 4: continuously from 60 minutes up to 30 days. If it is surgically invasive, Rule 7 applies. That rule places short-term surgically invasive devices in Class II unless an exception applies. Direct contact with the heart, the central circulatory system, or the central nervous system is Class IV. A biological effect, or absorption in whole or in large part, is Class IV. Ionizing radiation is Class III⁶. A stapler that is used only during the procedure and does not remain is a different duration. If that use is transitional — continuously less than 60 minutes — Rule 6 places it in Class II unless that rule's own exceptions apply. The energy exception in Rule 6 is ionizing radiation⁶. The circumcision-device page records NMPA Class II, registration Lu Mech Reg. 20172020238, and CE marking. Those are catalogue facts. They are not the Brazilian class. Article 5 paragraph 2 leaves a doubtful classification with ANVISA⁶. If the Brazilian class is I or II, the route is notification: IN 290/2024 does not apply, Article 13 does not ask for a CBPF, and Article 28 exempts the notification from revalidation. A CE mark still does not authorize importation.

Example B: Single-use 1470 nm laser fiber. Article 8 classifies the fiber and the laser console separately, and it classifies an accessory separately from the device it accompanies⁶. Article 4, item XI, says a device intended only to transmit energy, substances, or other elements between an active device and the patient, without producing a significant alteration, is not itself an active device⁶. If the fiber is surgically invasive and the ablation procedure is transitional, Rule 6's default is Class II. The great saphenous vein is not in the central-circulatory-system list in Article 4, item XLI (pulmonary arteries, aorta, coronary arteries, carotid arteries, cerebral arteries, brachiocephalic trunk, coronary veins, pulmonary veins, and the venae cavae). Laser light is not the ionizing-radiation exception that moves Rule 6 to Class III⁶. If the fiber is instead treated as an active therapeutic device that can supply energy in a potentially dangerous way, considering the nature, density, and site of application, Rule 9 places it in Class III⁶. Named optical-fiber rows already published by ANVISA have been Class III. The register comparison for fibers and generators records those rows and states that a row's Brazilian class is not a reason to relabel Medison's NMPA Class II fiber as a Class III system. The laser-fiber page records NMPA Class II, Lu Mech Reg. 20192010517. If the Brazilian class is III or IV, the route is registro, an NMPA registration does not open IN 290/2024, and Article 14 requires the CBPF or proof that the CBPF petition was filed, with the grant waiting on the published certificate. The consumable is regularized separately from a partner-supplied console.

Example C: Post-operative protective pants. Rule 1 places all non-invasive devices in Class I unless a later rule applies⁶. If the garment contacts injured skin, Rule 4 applies: a mechanical barrier, compression, or absorption of exudates is Class I; a device intended mainly to control the microenvironment of injured skin is Class II; other contact with injured skin is Class II⁶. The protective-pants page records an NMPA Class I filing, Lu Wei Mech Filing 20190014. That filing does not select the Brazilian rule. If the Brazilian class is I or II, the route is notification, with no CBPF in the Article 13 list and no revalidation under Article 28.

Distributor red flags before executing an import agreement

Prior to executing import arrangements or remitting commercial advances, verify that your transaction does not trigger these five operational red flags:

• Red Flag 1: The supplier presents a European CE certificate or an ISO 13485 audit report as if either document authorizes importation into Brazil. Fact: a device that has not been notified or registered is not regularized. Law nº 6.437/1977 makes breach of the sanitary rules a sanitary infraction, and IN 426/2026 Article 15 uses that same law for breaches of the UDI instruction.
• Red Flag 2: The holder says a Class III registro needs no factory GMP certificate. Fact: Article 14 of RDC 751/2022 accepts a published CBPF or proof that the CBPF petition has been filed so analysis can start, and it makes the grant conditional on publication of a valid CBPF. Voto nº 41/2026 states that Class III and IV files require the certificate and that Class I and II notifications do not.
• Red Flag 3: A consultant asserts that MDSAP GMP certification must be renewed every two years. Fact: Under RDC nº 850/2024, ANVISA expanded MDSAP CBPF validity to 4 full years.
• Red Flag 4: The distributor offers an ANVISA registration number that cannot be located in the Portal de Consultas or is registered under an unrelated commercial entity without formal transfer documentation under RDC 903/2024.
• Red Flag 5: The foreign factory producing Class I or II consumables has not established its electronic profile via Solicita Subject Code 80326, leaving the file without an authentic Código Único de Fabricante Internacional.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. The relevant catalogue lines for this decision are the disposable circumcision ring, which records CE marking, the circumcision anastomat kits, the NMPA-registered 1470 nm single-use medical laser fiber, and post-operative protective pants.

An NMPA registration or a CE mark is not Brazilian market clearance¹. The fiber-and-generator register comparison found no VEMERIX name among its laser-keyword hits in the regularized-device list. That extract is a laser-keyword screen, not a search of every product family. A buyer confirms any claimed ANVISA number in Portal de Consultas and in the DOU before treating a SKU as cleared.

Where VEMERIX fits is as the manufacturing and documentation partner for a Brazilian holder who is preparing the file. The documents a holder can request are:

• Technical file material the holder can put in the dossier: mechanical performance data, ISO 10993 biocompatibility reports, aging studies, and ethylene oxide sterilization validation, organized against the essential safety and performance requirements in RDC 848/2024.
• Quality-system documents structured to ISO 13485:2016 and RDC 665/2022, which a Brazilian holder can use in an MDSAP audit submitted for a CBPF. RDC 850/2024 makes a CBPF granted through MDSAP valid for 4 years. The catalogue does not state that a Medison plant already holds that Brazilian certificate.
• Legal-manufacturer documents the Brazilian holder needs for Solicita subject code 80326: corporate documents, apostilled business licenses, and the authorizations the notice requires. The Brazilian holder files the petition. The foreign factory does not obtain the authorization in its own name.
• The vascular boundary: Medison manufactures the NMPA-registered 1470 nm single-use optical fiber. VEMERIX does not manufacture the partner-supplied NOVACURE diode laser console, and that console is regularized by its own manufacturer.

For Brazilian distributors and Latin American medical device enterprises seeking to qualify our sterile product families or initiate ANVISA technical dossier compilation, explore our core urology and vascular portfolios—including the disposable circumcision device, the 1470 nm endovenous laser fiber, and post-operative protective care pants—or contact our regulatory affairs team to request technical dossier evaluation packs and regulatory cooperation agreements.

Frequently asked questions

Does a CE mark let a device into Brazil?
No. A European CE mark issued under the EU MDR is not a Brazilian market authorization. ANVISA operates complete regulatory sovereignty. Furthermore, CE marking is not recognized as an AREE authority under IN 290/2024 and does not confer any accelerated review rights in Brazil.

Can a foreign manufacturer hold the ANVISA authorization itself?
No. Under Brazilian federal legislation (Law 6.360/1976), a foreign corporate entity cannot hold an ANVISA registration or notification. A Brazilian-constituted company (the detentor) possessing a valid CNPJ, an AFE from ANVISA, and local sanitary licensing must act as the legal holder of record.

Do Class I and II notifications expire?
No. Article 28 of RDC 751/2022 exempts notified products from revalidation⁶. The English regulation page states that a Class I or II notification does not expire, and that it may be cancelled on request, on reassessment, where irregularities cannot be resolved, or where fraud is found¹.

How long is a registro valid and when must revalidation be filed?
Article 11 of RDC 751/2022 makes a marketing authorization valid for 10 years from DOU publication, renewable for an equal period⁶, ¹⁶. Article 27 paragraph 2 requires the revalidation petition within the period in RDC 250/2004. Voto nº 21/2026 restates that window as a maximum of 12 months and a minimum of 6 months before the expiration day. GGTPS stated in that file that missing the window leads to publication of caducidade, and that no current rule authorizes manufacture, import, or sale of a device whose registration was not revalidated¹⁶.

Is MDSAP enough for the Brazilian GMP certificate?
MDSAP is not an automatic waiver, but MDSAP audit reports issued by recognized Auditing Organizations can be submitted to ANVISA to obtain the Brazilian CBPF without requiring an on-site ANVISA inspection. Under RDC nº 850/2024, CBPFs granted via MDSAP remain valid for 4 years.

What changed for international manufacturers on 14 August 2026?
As of 14 August 2026, creation, alteration, and inactivation of foreign manufacturing plant records for Class I and II devices must be submitted exclusively via ANVISA's electronic Solicita portal under Subject Code 80326. This process generates the official Código Único de Fabricante Internacional, which is mandatory for all imported Class I and II device dossiers.

When must UDI data be transmitted to SIUD?
SIUD has been in operation since IN 426/2026 took effect on 1 March 2026¹⁰, ¹¹. Compulsory transmission, counted from that date under RDC 591/2021 Article 15 as amended by RDC 884/2024, is Class IV by 1 September 2029, Class III by 1 March 2030, Class II by 1 March 2031, and Class I by 1 March 2032¹¹, ²². Label marking is earlier. Ofício Circular nº 2/2025 states that Class IV devices manufactured from 10 July 2025 must already carry the UDI on the label and packaging, with Class III, II, and I following on 10 January 2026, 2027, and 2028²³.

Is any VEMERIX product authorized by ANVISA?
No VEMERIX or Medison product currently holds ANVISA authorization in public records. We partner with qualified Brazilian distributors and regulatory holding firms, supplying comprehensive technical files, biocompatibility dossiers, and quality certifications to support their domestic registration filings.